1st Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$3,200,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions Orphan Drug Tax Mobile Workforce Thin Capitalization Rules 163(j) Base Erosion Surtax Tax Cuts & Jobs Act Implementation Innovation Box Expended FDII

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Commerce, Dept of (DOC); White House Office; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

H.R. 1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 Biosimilars Medicare Part D Drug Pricing Part B Outcomes Based Contracts Generics Innovative Pharmaceuticals Cell and Gene Therapy Medicaid Alternative Payment Models

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); White House Office; SENATE; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB)

Bills named: S. 377 (116th), H.R. 1046 (116th)

Trade (domestic/foreign) TRD

Free Trade Agreements - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and Market Access Issues Sub-standards Medicines Quality of Medicines International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Columbia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA Re-negotiation USTR Special 301 Report/National Trade Estimate Trade Policy KORUS Tariffs CFIUS

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Commerce, Dept of (DOC); White House Office; Office of Management & Budget (OMB); SENATE; U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

S.659 - Biologic Patent Transparency Act Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection issues Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents Inter Partes Review at PTO Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH New —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); State, Dept of (DOS); Health & Human Services, Dept of (HHS); SENATE; White House Office; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); U.S. Agency for International Development (USAID)

Bills named: S. 659 (116th)

Health Issues HCR

HR 938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics Act HR 1520: Purple Book Continuity Act HR 1503: Orange Book Transparency Act HR 1499: Protecting Consumer Access to Generic Drugs Act HR 2113:Speeding Access to Already Approved Pharmaceuticals Act of 2017 Senate SPIKE Act Fast Generics Cell & Gene Therapy, including reimbursement 340B Drug Discount Program Drug Importation REMS Creates Act Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Outcomes based Contracting Part D Non-interference Orphan Drugs Drug Pricing Transparency Clinical Trials Virtual Clinical Trials Part D Donut Hole Biosimilar Pass Through Payments Value Based Pricing

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Food & Drug Administration (FDA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; White House Office; Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1520 (116th), H.R. 938 (116th), H.R. 2113 (116th), H.R. 1503 (116th), H.R. 1499 (116th)

Foreign Relations FOR

Foreign Investment Risk Review Modernization Act of 2017 (FIRMMA) CFIUS Reform Foreign Agents Registration Act (FARA) Reform Treasury

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; White House Office; U.S. Agency for International Development (USAID); SENATE; Commerce, Dept of (DOC)

Budget/Appropriations BUD

FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) Reconciliation Gx Drug Labeling Biosimilars Importation Drug Pricing Value of Meds

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
NORA CONNORS —
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SHAWN O'NEAIL —

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); White House Office; State, Dept of (DOS); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.